title: Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status.
abstract: Pleiotrophin (PTN), a tightly regulated angiogenic and mitogenic heparin-binding protein, is markedly elevated in a variety of aggressive solid tumours. The role of PTN in haematological malignancies, however, has not been previously evaluated. This study demonstrated that PTN serum levels were elevated in multiple myeloma (MM) patients when compared with healthy subjects (P < 0.0001). Serum levels of this protein significantly increased during progression of disease, and decreased during response to anti-MM therapy (P < 0.001). These results suggest that serum PTN may be a new biomarker for monitoring the disease status and therapeutic response of MM patients.
authors: Institute for Myeloma and Bone Cancer Research, 9201 W. Sunset Boulevard, West Hollywood, CA 90069, USA.
authors: Howard S
authors: HS
authors: Yeh
authors: Haiming
authors: H
authors: Chen
authors: Steven J
authors: SJ
authors: Manyak
authors: Regina A
authors: RA
authors: Swift
authors: Richard A
authors: RA
authors: Campbell
authors: Cathy
authors: C
authors: Wang
authors: Mingjie
authors: M
authors: Li
authors: Hee Jin
authors: HJ
authors: Lee
authors: Gabriel
authors: G
authors: Waterman
authors: Melinda S
authors: MS
authors: Gordon
authors: Jonathan
authors: J
authors: Ma
authors: Benjamin
authors: B
authors: Bonavida
authors: James R
authors: JR
authors: Berenson